Haematopoietic Stem Cell Transplantation in Children

Haematopoietic stem cell transplantation in children

• R M Egeler
• G Dini

Survey on haematopoietic stem cell transplantation for children in Europe

• M Miano
• R Cancedda
• on behalf of the EBMT Paediatric Diseases Working Party

Allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia: the BFM/IBFM/EBMT concepts

• C Peters
• A Schrauder
• on behalf of the BFM Study Group, the IBFM-Study Group and the Paediatric Disease Working Party of the EBMT

Stem cell transplantation for aplastic anemia and myelodysplastic syndrome

• J Starý
• F Locatelli
• on behalf of the European Working Group on Myelodysplastic Syndrome (EWOG-MDS) and Pediatric Diseases Working Party of the EBMT

Hematopoietic transplantation for bone marrow failure syndromes and thalassemia

• J Sevilla
• S Fernández-Plaza
• on behalf of the Paediatric Disease Working Party of the EBMT

Hematopoietic cell transplantation activity in Europe for inherited metabolic diseases: open issues and future directions

• A M Rovelli
• C G Steward

Treatment of refractory autoimmune diseases with autologous stem cell transplantation: focus on juvenile idiopathic arthritis

• N M Wulffraat
• B Vastert
• A Tyndall

Evolving role of myeloablative chemotherapy in the treatment of childhood brain tumours

• S Dallorso
• G Dini
• on behalf of EBMT-PDWP

Graft dysfunction and delayed immune reconstitution following haploidentical peripheral blood hematopoietic stem cell transplantation

• L M Ball
• A C Lankester
• R M Egeler

The hope and the reality of reduced intensity transplants in children with malignant diseases

• J Stein
• G Dini
• on behalf of the Pediatric Diseases Working Party of the EBMT

Stem cell transplantation for congenital immunodeficiencies using reduced-intensity conditioning

• P Veys
• K Rao
• P Amrolia

Is there a role for minimal residual disease levels in the treatment of ALL patients who receive allogeneic stem cells?

• M W Schilham
• A Balduzzi
• on behalf of the PD-WP of the EBMT

Immune reconstitution following hematopoietic progenitor cell transplantation: challenges for the future

• T J Fry
• C L Mackall

Immunotherapy in allogeneic hematopoietic stem cell transplantation – not just a case for effector cells

• A Troeger
• R Meisel
• D Dilloo

Novel approaches in GVHD therapy

• J Svennilson
• on behalf of the Paediatric Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

Update on extracorporeal photochemotherapy for graft-versus-host disease treatment

• J Kanold
• C Messina
• on behalf of the Paediatric Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

Adenovirus infection in children after allogeneic stem cell transplantation: diagnosis, treatment and immunity

• M J D van Tol
• E C J Claas
• M W Schilham

Late effects after stem cell transplantation (SCT) in children – growth and hormones

• M B Ranke
• C P Schwarze
• on behalf of the PDWP of the BMT

Secondary malignancies and quality of life after stem cell transplantation

• J J Ortega
• T Olivé
• A Llort

The polymorphisms −318C>T in the promoter and 49A>G in exon 1 of CTLA4 and the risk of aplastic anemia in a Caucasian population

• J Svahn
• M Capasso
• A Iolascon

Free Papers

Poster Presentation